Crizotinib

CHEMBL601719 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

450.3 g/mol

LogP

3.7

Phase

4

An oral tyrosine kinase inhibitor that blocks ALK, ROS1, and MET signaling proteins driving certain lung and other cancers, particularly non-small cell lung cancer with ALK or ROS1 gene rearrangements. It was one of the first targeted therapies to demonstrate dramatic responses based on tumor genetics.

Masse moléculaire

450,3000 g/mol

LogP

3,70

TPSA

78,00 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Mécanisme d'action

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl

InChI

InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

Molecular Formula

C21H22Cl2FN5O

HBD / HBA

2 / 6

Liaisons Rotatives

5

Atomes Lourds

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An oral tyrosine kinase inhibitor that blocks ALK, ROS1, and MET signaling proteins driving certain lung and other cancers, particularly non-small cell lung cancer with ALK or ROS1 gene rearrangements. It was one of the first targeted therapies to demonstrate dramatic responses based on tumor genetics.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Crizotinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL601719. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11626560. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Crizotinib sur PillFYI

Structure

Données Clés

Formule: C21H22Cl2FN5O
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.